BioSig Technologies Begins Trading on Nasdaq
September 21 2018 - 8:00AM
BioSig Technologies, Inc. (NASDAQ:BSGM) a medical device company
developing a proprietary biomedical signal processing platform
designed to address an unmet technology need for the $4.6 billion
electrophysiology (EP) marketplace, today announced that shares of
its common stock have begun officially trading on the Nasdaq
Capital Market, under the ticker “BSGM”.
BioSig’s listing on the Nasdaq is the Company’s most recent
operational achievement. In August 2018, the Company received
510(k) clearance from the FDA for their patented advanced signal
acquisition and processing technology, PURE EP(tm) System. The
non-invasive technology is a computerized system intended to
enhance electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory
for the treatments of arrhythmia, or irregular heartbeat. The
Company completed 13 pre-clinical studies at Mayo Clinic and Mount
Sinai to date and received first units from its contract
manufacturer, Minnetronix, in September 2018. BioSig recently made
an announcement about their ongoing progress with effective
physician engagement and continues to add experienced industry
hires to its clinical and commercial teams.
“The Nasdaq stock exchange is home to many of the world’s most
innovative medical technology and healthcare companies and is a
natural fit for BioSig,” stated Mr. Kenneth Londoner, Founder,
Chairman and CEO of BioSig Technologies. “Our listing on the
Nasdaq exchange is a milestone and reflects the significant
progress we have made in strengthening our corporate governance and
expanding our industry footprint.”
Analysts forecast the global market for EP devices will grow at
a 10.6 percent compound annual growth rate to more than $8.5
billion by 2024*, making it one of the fastest growing medical
device segments. In the United Stated alone, the number of Atrial
Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia
ablations is forecast to grow at 11 percent from 2015 to
2020**.
*EP device growth forecast from Electrophysiology Market by
Devices Analysis, Market Research Engine, July 2017.**Cardiac
ablations growth forecast from Global Opportunities in Medical
Devices & Diagnostics, Health Research International, 2016
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a
proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to
commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing
market.
The Company’s first product, PURE EP™ System, is a novel cardiac
signal acquisition and display system which is engineered to assist
electrophysiologists in clinical decision-making during procedures
to diagnose and treat patients with abnormal heart rates and
rhythms. BioSig’s main goal is to deliver technology to improve
upon catheter ablation treatments for the prevalent and potentially
deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and has received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12600 Hill Country Blvd R-275
Austin, TX 78738
nrusskina@biosigtech.com
512-329-2643
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024